Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

• Published in: JAMA : the journal of the American Medical Association Vol. 257; no. 23; p. 3233
• Main Authors: Blankenhorn, D H, Nessim, S A, Johnson, R L, Sanmarco, M E, Azen, S P, Cashin-Hemphill, L
• Format: Journal Article
• Language: English
• Published: United States 19.06.1987
• Subjects: Adult; Clinical Trials as Topic; Colestipol - therapeutic use; Coronary Artery Bypass; Coronary Artery Disease - blood; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - drug therapy; Drug Therapy, Combination; Graft Occlusion, Vascular - blood; Graft Occlusion, Vascular - diagnostic imaging; Graft Occlusion, Vascular - drug therapy; Humans; Lipids - blood; Male; Middle Aged; Niacin - therapeutic use; Polyamines - therapeutic use; Radiography; Random Allocation

The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery. During two years of treatment there was a 26% r...